|
|
|||||||||
|
|
NeoReviews Vol.9 No.11 2008 e526
© 2008 American Academy of Pediatrics
* Department of Pediatrics, Carver College of Medicine, The University of Iowa, Iowa City, Ia
Because red blood cell (RBC) transfusion therapy remains the primary treatment of anemia encountered in early life, the basis for RBC transfusion in the treatment of symptomatic anemia is discussed in this review along with several important aspects of neonatal blood banking practices. Nontransfusion approaches to the prevention and treatment of neonatal anemia also are described. Finally, this review covers the controversy surrounding whether neonatal RBC transfusion therapy should be restrictive or liberal. The evaluation and treatment of uncommon and rare acquired and genetic causes of anemia in newborn infants are beyond the scope of this review.
Abbreviations: AOP: anemia of prematurity CMV: cytomegalovirus EPO: erythropoietin GVHD: graft versus host disease Hb: hemoglobin HIV: human immunodeficiency virus NICU: neonatal intensive care unit RBC: red blood cell r-HuEPO: recombinant human erythropoietin VLBW: very low-birthweight WBC: white blood cell
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | CME | ARCHIVE | SEARCH | TABLE OF CONTENTS |